John Nolan

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Peter D. Davis, Graeme J. Dougherty, David C. Blakey et al. · Oxford University Research Archive (ORA) (University of Oxford) · 2002 · 231 citations

Endothelial Cell Morphology, Chemoprevention Strategy, Tumor Biology +17

The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro

Olga Piskareva, Harry Harvey, John Nolan et al. · Cancer Letters · 2015 · 90 citations · Full text

Cisplatin Resistance, Cross Resistance, Developmental Biology +15

Indolequinone Antitumor Agents:  Reductive Activation and Elimination from (5-Methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl Derivatives and Hypoxia-Selective Cytotoxicity in Vitro

Matthew A. Naylor, Elizabeth Swann, Steven A. Everett et al. · Journal of Medicinal Chemistry · 1998 · 69 citations

A physiologically relevant 3D collagen-based scaffold–neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models

Caroline M. Curtin, John Nolan, Ronald A. Conlon et al. · Acta Biomaterialia · 2018 · 62 citations · Full text

Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine

Adams Ge, J. Godden, John Nolan et al. · British Journal of Cancer · 1988 · 59 citations · Full text

Pharmaceutical Science, Medicine, Anti-tumour Effect +6